Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

Inclusion Criteria:

• Diagnosis of probable Alzheimer's disease using NINCDS-ADRDA criteria

• Mild to moderate degree of severity of dementia as assessed by the Mini-MentalStatus Examination score of 16 to 26 (inclusive)

• Potential participant may be treated with conventional Alzheimer's diseasetherapy and must be on a stable dose for at least 6 months prior to therandomization and during the entire study period

• Potential participant must have a reliable caregiver and must be living in acommunity or in an assisted living facility

• Mother tongue is English, Spanish or French (oral and written fluency)

• Signed informed consent from potential participant or legal representative andidentified caregiver

Exclusion Criteria:

• Potential participant with any other cause of dementia.

• Potential participant with serious health problems other than Alzheimer's disease

• Use of an investigational drug within two months prior to randomization or during thisstudy